Forbes not good

"Value Line forecasts that Teva's growth will slow this year from competition for generic epilepsy drug Gabapentin and multiple sclerosis treatment Copaxone, which is its signal proprietary (that is, nongeneric) product."

-Elizabeth MacDonald (senior editor !!?!? wha!!?!??!?)
Forbes, May 9, 2005

hmmm...is it just me or does that make no sense at all. It you replace signal with single, then you're getting somewhere.